• LAST PRICE
    432.2400
  • TODAY'S CHANGE (%)
    Trending Down-1.2400 (-0.2861%)
  • Bid / Lots
    431.8700/ 2
  • Ask / Lots
    432.5800/ 1
  • Open / Previous Close
    434.1300 / 433.4800
  • Day Range
    Low 432.2000
    High 437.0000
  • 52 Week Range
    Low 283.6000
    High 448.4000
  • Volume
    47,011
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 433.48
TimeVolumeVRTX
09:32 ET25971433.5
09:33 ET608434.9602
09:35 ET4119433.845
09:37 ET1031433.4832
09:39 ET1600432.24
09:42 ET159432.24
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesVRTX
Vertex Pharmaceuticals Inc
112.0B
31.1x
+46.35%
United StatesREGN
Regeneron Pharmaceuticals Inc
108.6B
28.3x
+10.93%
United States
32.5B
---
-18.14%
United StatesMRNA
Moderna Inc
35.9B
-7.6x
---
United StatesIQV
IQVIA Holdings Inc
44.9B
33.8x
+46.62%
United StatesICLR
ICON PLC
26.3B
43.3x
+4.68%
As of 2024-02-27

Company Information

Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on investing in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has four approved medicines that treat the underlying cause of cystic fibrosis (CF), and one approved therapy that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT). Its pipeline includes clinical-stage programs in CF, SCD, TDT, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency. Its marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). It is developing non-autologous (allogeneic) fully differentiated, stem-cell derived islet cell therapies designed to replace insulin-producing islet cells that are destroyed in people with T1D.

Contact Information

Headquarters
50 Northern AvenueBOSTON, MA, United States 02210
Phone
617-341-6393
Fax
---

Executives

Executive Chairman of the Board
Jeffrey Leiden
President, Chief Executive Officer, Director
Reshma Kewalramani
Chief Financial Officer, Executive Vice President
Charles Wagner
Chief Operating Officer, Executive Vice President
Stuart Arbuckle
Executive Vice President - Global Research, Chief Scientific Officer
David Altshuler

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$112.0B
Revenue (TTM)
$9.9B
Shares Outstanding
258.3M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.36
EPS
$13.89
Book Value
$68.22
P/E Ratio
31.1x
Price/Sales (TTM)
11.3
Price/Cash Flow (TTM)
29.5x
Operating Margin
38.83%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.